

# Table of Contents

<b>CHAPTER 1: HEART FAILURE</b> .....	<b>15</b>
DEFINITION AND EPIDEMIOLOGY.....	15
CLASSIFICATION OF HEART FAILURE .....	16
1. <i>Classification by Duration and Onset: Acute vs. Chronic Heart Failure</i> .....	16
2. <i>Classification Based on Left Ventricular Ejection Fraction</i> .....	16
3. <i>Classification by Ventricular Dysfunction: Systolic vs. Diastolic</i> .....	17
4. <i>Functional Classification–New York Heart Association (NYHA)</i> .....	17
5. <i>Staging–American College of Cardiology / American Heart Association (ACC/AHA) and Heart–Lung–Metastasis (HLM) Systems</i> .....	18
6. <i>Hemodynamic Classification: Warm/Cold and Wet/Dry Profiles</i> .....	18
7. <i>Aetiological Classification</i> .....	19
7.1. <i>Ischemic Heart Failure</i> .....	20
7.2. <i>Non-Ischemic Heart Failure</i> .....	20
8. <i>Forward vs. Backward Heart Failure</i> .....	21
9. <i>High-Output vs. Low-Output Heart Failure</i> .....	21
CLINICAL PRESENTATION AND DIAGNOSIS.....	22
<i>Diagnostic Algorithm for Heart Failure</i> .....	22
1. <i>Initial Clinical Assessment</i> .....	22
2. <i>Natriuretic Peptide Testing</i> .....	23
3. <i>Electrocardiography (ECG)</i> .....	23
4. <i>Chest Imaging</i> .....	24
5. <i>Echocardiography</i> .....	24
6. <i>Laboratory Studies</i> .....	24
7. <i>Advanced Testing</i> .....	24
<i>Integrating Classifications Within the Diagnostic Process</i> .....	28
MANAGEMENT OF HEART FAILURE .....	28
1. <i>Chronic heart failure with reduced ejection fraction</i> .....	28
1.1. <i>Pharmacological management of HFrEF</i> .....	29
1.1.1. <i>Angiotensin-converting enzyme inhibitor</i> .....	29
1.1.2. <i>Beta-blockers</i> .....	29
1.1.3. <i>Mineralocorticoid receptor antagonists</i> .....	30
1.1.4. <i>Sodium-Glucose Transport Protein 2 inhibitors</i> .....	30
1.1.5. <i>Angiotensin receptor–neprilysin inhibitor</i> .....	30
1.1.6. <i>Angiotensin II receptor blockers</i> .....	31
1.1.7. <i>Loop diuretics</i> .....	31
1.1.8. <i>Ivabradine</i> .....	31
1.1.9. <i>Vericiguat</i> .....	32
1.1.10. <i>Hydralazine + isosorbide dinitrate</i> .....	32
1.1.11. <i>Digoxin</i> .....	32
1.1.12. <i>Intravenous Iron Supplementation</i> .....	32
1.1.13. <i>Inotropes (Short-Term or Palliative Use)</i> .....	33
1.2. <i>Non-pharmacological management of HFrEF</i> .....	33

1.2.1. Cardiac Resynchronisation Therapy .....	33
1.2.2. Implantable Cardioverter-Defibrillator .....	36
1.2.3. Left Ventricular Assist Device .....	36
1.2.4. Temporary Mechanical Circulatory Support .....	36
1.2.5. Heart Transplantation .....	38
1.2.6. Palliative and Supportive Care.....	38
2. Chronic heart failure with mildly reduced ejection fraction.....	38
3. Chronic heart failure with preserved ejection fraction .....	39
4. Acute heart failure .....	39
4.1. Loop Diuretics .....	40
4.2. Vasodilators .....	40
4.3. Inotropes .....	40
4.4. Vasopressors.....	40
4.5. Ultrafiltration .....	41
4.6. Temporary Mechanical Circulatory Support.....	41
4.7. Initiation or Reintroduction of Chronic GDMT .....	43
TAKE-HOME MESSAGE .....	43
STUDY NOTES.....	43
REFERENCES .....	44
<b>CHAPTER 2: ISCHEMIC HEART DISEASE .....</b>	<b>49</b>
DEFINITION AND EPIDEMIOLOGY .....	49
CLASSIFICATION AND AETIOLOGY OF ISCHEMIC HEART DISEASE .....	50
1. Chronic Ischemic Heart Disease (Chronic Coronary Syndromes).....	50
2. Acute Ischemic Heart Disease (Acute Coronary Syndromes) .....	53
2.1. Pathophysiology and Aetiological Classification .....	54
2.1.1. Thrombotic Causes .....	54
2.1.2. Non-Thrombotic Causes.....	54
2.2. Clinical Classification of ACS .....	55
2.2.1. Unstable Angina .....	55
2.2.2. Non-ST-Elevation Myocardial Infarction.....	55
2.2.3. ST-Elevation Myocardial Infarction .....	56
2.3. Scoring Systems for ACS Severity and Prognosis.....	56
2.3.1. Killip–Kimball Classification.....	56
2.3.2. GRACE Score (Global Registry of Acute Coronary Events).....	56
2.3.3. Universal definition of myocardial infarction .....	57
DIAGNOSTIC WORKFLOW FOR CHRONIC CORONARY SYNDROME .....	58
Step 1: Clinical Likelihood Assessment .....	59
Step 2: Testing Based on Pre-Test Probability.....	59
Step 3: Coronary Angiography.....	60
DIAGNOSTIC WORKFLOW FOR ACUTE CORONARY SYNDROMES.....	62
1. Immediate Clinical and ECG Evaluation.....	63
2. Serial Cardiac Biomarkers, Rapid Troponin Rule-In/Rule-Out (0 h/1 h or 0 h/2 h Protocols).....	63
Rule-Out Zone .....	64
Rule-In Zone.....	64

Observe Zone.....	64
3. <i>Risk-Based Timing of Coronary Angiography</i> .....	66
MANAGEMENT OF CHRONIC CORONARY SYNDROME.....	69
1. <i>Lifestyle and Risk Factor Management</i> .....	70
1.1. Patient Education .....	70
1.2. Smoking and Substance Use .....	70
1.3. Nutrition and Weight Control .....	70
1.4. Alcohol and Psychosocial Health .....	71
2. <i>Physical Activity and Cardiac Rehabilitation</i> .....	71
3. <i>Antianginal Therapy</i> .....	71
First-Line Agents .....	71
3.1. Beta-blockers .....	71
3.2. Dihydropyridine Calcium Channel Blockers.....	71
3.3. Non-dihydropyridine Calcium Channel Blockers .....	72
3.4. Short-acting Nitrates .....	72
Second-Line and Adjunct Agents.....	72
3.5. Long-acting Nitrates.....	72
3.6. Ivabradine.....	73
3.7. Ranolazine.....	73
3.8. Trimetazidine .....	73
3.9. Nicorandil.....	73
4. <i>Antithrombotic Therapy</i> .....	73
4.1. Aspirin .....	74
4.2. Clopidogrel.....	74
4.3. Ticagrelor.....	74
4.4. Dual Antiplatelet Therapy .....	74
4.5. Extended Antithrombotic Strategies .....	75
5. <i>lipid-lowering therapy</i> .....	75
5.1. Statins .....	75
5.2. Ezetimibe.....	76
5.3. Proprotein convertase subtilisin/kexin type 9 Inhibitors (evolocumab, alirocumab) ...	76
5.4. Bempedoic Acid.....	76
Treatment Goals .....	76
6. <i>RAAS Inhibitors (ACE Inhibitors / ARBs)</i> .....	77
7. <i>Glucose-lowering therapy</i> .....	77
7.1. Sodium-glucose cotransporter 2 inhibitors.....	77
7.2. Glucagon like peptide-1 Receptor Agonists .....	78
8. <i>Anti-inflammatory Therapy</i> .....	78
Colchicine.....	78
9. <i>Revascularisation Strategies</i> .....	79
10. <i>Ischemia with No Obstructive Coronary Arteries and Angina with No Obstructive Coronary Arteries Considerations</i> .....	80
MANAGEMENT OF ACUTE CORONARY SYNDROMES.....	81
1. <i>Initial Medical Therapy Prior to Reperfusion in STEMI</i> .....	82
2. <i>Reperfusion strategies in STEMI</i> .....	83
2.1 <i>Percutaneous Coronary Intervention</i> .....	84

2.2. When to Choose PCI vs. CABG .....	85
3. Post-Reperfusion and Long-Term Management.....	85
4. Management of acute phase of NSTEMI-ACS .....	88
4.1 Antithrombotic Therapy in NSTEMI-ACS (before PCI) .....	88
4.2. Anticoagulation Therapy in NSTEMI-ACS (before PCI) .....	89
4.3. Maintenance Therapy and Bleeding Risk Mitigation (after PCI, or in case of conservative management without PCI) .....	90
4.4. Special Considerations: Oral Anticoagulation .....	91
5. Post-Acute Management of NSTEMI-ACS and Secondary Prevention.....	91
5.1. Recognition and Management of Complications.....	92
5.2. Cardiac Rehabilitation and Lifestyle Modifications.....	92
TAKE-HOME MESSAGE.....	93
STUDY NOTES .....	94
REFERENCES .....	96

**CHAPTER 3: VALVULAR HEART DISEASE ..... 103**

DEFINITION AND EPIDEMIOLOGY .....	103
CLASSIFICATION AND AETIOLOGY OF AORTIC VALVE DISEASE.....	104
1. Aortic Stenosis .....	105
1.1. Degenerative (calcific) aortic stenosis.....	105
1.2. Congenital aortic stenosis (primarily bicuspid aortic valve) .....	105
1.3. Rheumatic aortic stenosis .....	105
2. Aortic Regurgitation .....	105
2.1. Primary (valve leaflet) Aortic Regurgitation .....	106
2.2. Secondary (aortic root or annular dilation) Aortic Regurgitation .....	106
CLASSIFICATION AND AETIOLOGY OF MITRAL VALVE DISEASE .....	106
1. Mitral Stenosis .....	106
1.1. Rheumatic Mitral Stenosis.....	106
1.2. Degenerative Mitral Stenosis (mitral annular calcification-related).....	106
1.3. Other causes .....	107
2. Mitral Regurgitation.....	107
2.1. Primary (degenerative) Mitral Regurgitation .....	107
2.2. Secondary (functional) Mitral Regurgitation .....	107
OTHER VALVULAR LESIONS: TRICUSPID AND PULMONARY VALVE DISEASE.....	108
1. Tricuspid Valve Disease .....	108
2. Pulmonary Valve Disease.....	109
DIAGNOSIS OF VALVULAR (AORTIC, MITRAL) HEART DISEASE .....	109
Clinical Assessment.....	109
Transthoracic Echocardiography .....	110
Transoesophageal Echocardiography.....	113
Stress Echocardiography and functional testing.....	114
Computed Tomography.....	114
Cardiac Magnetic Resonance Imaging.....	114
Integrated Assessment.....	115

MANAGEMENT OF AORTIC VALVE DISEASE .....	115
<i>Medical Therapy</i> .....	115
<i>Indications for Intervention</i> .....	116
<i>Choice of Intervention</i> .....	117
<i>Follow-Up and Serial Testing</i> .....	119
<i>Post-Surgical Considerations and Anticoagulation Therapy</i> .....	119
MANAGEMENT OF MITRAL VALVE DISEASE.....	120
<i>Medical Therapy</i> .....	120
<i>Indications for Intervention</i> .....	121
<i>Choice of Intervention</i> .....	124
<i>Follow-Up and Serial Testing</i> .....	126
<i>Post-Surgical Considerations and Anticoagulation Therapy</i> .....	126
TAKE-HOME MESSAGE .....	127
STUDY NOTES.....	127
REFERENCES .....	129
<b>CHAPTER 4: INFECTIVE ENDOCARDITIS .....</b>	<b>133</b>
DEFINITION AND EPIDEMIOLOGY.....	133
CLASSIFICATION AND AETIOLOGY OF INFECTIVE ENDOCARDITIS .....	134
1. <i>Classification by Valve and Device Involvement</i> .....	134
1.1 Native Valve Endocarditis (NVE) .....	134
Native Valve Endocarditis .....	134
1.2 Prosthetic Valve Endocarditis (PVE) .....	134
Prosthetic Valve Endocarditis .....	134
1.3 Cardiac Device-Related Infective Endocarditis.....	135
1.4 Right-Sided Endocarditis .....	135
2. <i>Classification by Mode of Acquisition</i> .....	135
2.1 Community-Acquired Infective Endocarditis .....	135
2.2 Healthcare-Associated Infective Endocarditis.....	135
2.3 Nosocomial Infective Endocarditis .....	135
3. <i>Microbiological Aetiology</i> .....	135
4. <i>Risk Factors</i> .....	136
DIAGNOSIS OF INFECTIVE ENDOCARDITIS.....	137
1. <i>Clinical Assessment</i> .....	138
2. <i>Blood culture</i> .....	139
2.1. When Blood Cultures Are Negative .....	139
3. <i>Echocardiography</i> .....	140
4. <i>Applying the Modified Duke Criteria</i> .....	141
4.1. Major criteria .....	142
4.2. Minor criteria .....	142
4.3. Diagnosis .....	142
MANAGEMENT OF INFECTIVE ENDOCARDITIS.....	143
1. <i>Principles of Management</i> .....	143
2. <i>Empirical Antibiotic Therapy</i> .....	143

3. <i>Pathogen-Directed Therapy</i> .....	144
4. <i>Duration of Therapy and Monitoring</i> .....	145
4.1. Factors Influencing Duration .....	145
4.2. How to Know When to Stop.....	145
4.3. What Prolonged Therapy Means.....	146
4.4. Monitoring Requirements .....	146
4.5. When to Reassess.....	147
4.6. Switching to Oral or Outpatient Therapy .....	147
5. <i>Indications for Surgery</i> .....	147
5.1. Heart Failure Due to Valve Dysfunction .....	147
5.2. Uncontrolled Infection Despite Optimal Medical Therapy.....	148
5.3. Prevention of Recurrent Embolism.....	148
5.4. Additional Considerations .....	148
5.5. Timing of Surgery.....	148
5.6. Special Situations: Neurological Complications .....	149
5.7. The Role of Multidisciplinary Care .....	149
6. <i>Prevention and Patient Education</i> .....	149
6.1. Identification of High-Risk Groups.....	149
6.2. Antibiotic Prophylaxis.....	150
6.2.1. Antibiotic Prophylaxis for Oral Procedures .....	150
6.2.2. Antibiotic Prophylaxis for Non-Dental Invasive Procedures .....	150
6.2.3. Peri-Operative Prophylaxis for Cardiac Device and Valve Implantation.....	150
6.3. Oral Health and Hygiene.....	150
6.4. Skin Care and Wound Management .....	151
6.5. Lifestyle Counselling.....	151
TAKE-HOME MESSAGE .....	151
STUDY NOTES.....	151
REFERENCES .....	153